Studies recruiting patients with Diabetic Kidney Disease
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease
Site PI: Dr. Daniel Weiner
Contact: dweiner@tuftsmedicalcenter.org
​Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
Site PI: Dr. Lesley Inker
Contact: linker@tuftsmedicalcenter.org
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes (PERL-FENO)
NIH-funded pilot study of fenofibrate to prevent kidney function decline in patients with Type 1 Diabetes and diabetic kidney disease.